Evidence mapPaperPMID 18599521Full record

ArticleDiabetes2008

Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins.

Shuhei Kawahara, Yasuaki Hata, Takeshi Kita, Ryoichi Arita, Muneki Miura, Shintaro Nakao, Yasutaka Mochizuki, Hiroshi Enaida, Tadahisa Kagimoto, Yoshinobu Goto and 2 more

Open access · greenAbstract read
In one paragraph

Article in Diabetes, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Proliferative Vitreoretinopathy: A Reappraisal.Journal of clinical medicine · 2023
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. [Proliferative vitreoretinopathy prophylaxis : Mission (im)possible].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Repurposing simvastatin as a therapy for preterm labor: evidence from preclinical models.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019
    Article
  14. Proliferative Vitreoretinopathy: A Review.International ophthalmology clinics · 2019
    Review
  15. 'Statins in retinal disease'.Eye (London, England) · 2018
    Review
  16. Article
  17. Soluble form of LR11 is highly increased in the vitreous fluids of patients with idiopathic epiretinal membrane.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2017
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Shuhei KawaharaDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Maidashi, Higashi-Ku, Fukuoka, Japan.
Yasuaki Hata
Takeshi Kita
Ryoichi Arita
Muneki Miura
Shintaro Nakao
Yasutaka Mochizuki
Hiroshi Enaida
Tadahisa Kagimoto
Yoshinobu Goto
Ali Hafezi-Moghadam
Tatsuro Ishibashi
Kyushu University · JPMassachusetts Eye and Ear Infirmary · US

Funding

P30 Core Grant for Vision ResearchP30EY014104 · MASSACHUSETTS EYE AND EAR INFIRMARY · 2002 to 2025
$2.8M
Mechanisms of Selectin Shedding in Leukocyte RecruitmentK08AI050775 · MASSACHUSETTS EYE AND EAR INFIRMARY · 2002 to 2004
$377k
NEI NIH HHS EY14104NEI NIH HHS P30 EY014104NHLBI NIH HHS HL086933NHLBI NIH HHS R01 HL086933NIAID NIH HHS AI050775NIAID NIH HHS K08 AI050775
6 · The paper itself

Abstract

objectiveDespite tremendous progress in vitreoretinal surgery, certain postsurgical complications limit the success in the treatment of proliferative vitreoretinal diseases (PVDs), such as proliferative diabetic retinopathy (PDR) and proliferative vitreoretinopathy (PVR). One of the most significant complications is the cicatricial contraction of proliferative membranes, resulting in tractional retinal detachment and severe vision loss. Novel pharmaceutical approaches are thus urgently needed for the management of these vision-threatening diseases. In the current study, we investigated the inhibitory effects of statins on the progression of PVDs. RESEARCH DESIGN AND

methodsHuman vitreous concentrations of transforming growth factor-beta2 (TGF-beta2) were measured by enzyme-linked immunosorbent assay. TGF-beta2-and vitreous-dependent phosphorylation of myosin light chain (MLC), a downstream mediator of Rho-kinase pathway, and collagen gel contraction simulating cicatrical contraction were analyzed using cultured hyalocytes. Inhibitory effects of simvastatin on cicatrical contraction were assessed both in vitro and in vivo.

resultsHuman vitreous concentrations of TGF-beta2 were significantly higher in the samples from patients with PVD compared with those without PVD. Simvastatin inhibited TGF-beta2-dependent MLC phosphorylation and gel contraction in a dose- and time-dependent manner and was capable of inhibiting translocation of Rho protein to the plasma membrane in the presence of TGF-beta2. Vitreous samples from patients with PVD enhanced MLC phosphorylation and gel contraction, whereas simvastatin almost completely inhibited these phenomena. Finally, intravitreal injection of simvastatin dose-dependently prevented the progression of diseased states in an in vivo model of PVR.

conclusionsStatins might have therapeutic potential in the prevention of PVDs.

Indexed as

AnimalsBiological TransportBlotting, WesternCattleCell MembraneCells, CulturedCollagenDiabetic RetinopathyElectroretinographyEnzyme-Linked Immunosorbent AssayHumansHypolipidemic AgentsIn Situ Nick-End LabelingMicroscopy, Electron, TransmissionMyosin Light ChainsPhosphorylationCollagenHypolipidemic AgentsMyosin Light Chainsrho GTP-Binding ProteinsSimvastatinTransforming Growth Factor beta2

Identifiers

PMID18599521
PMCPMC2551690
OpenAlexW1565176376

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.